Treats delayed neutrophil recovery or graft failure after autologous or allogeneic bone…. Sold as Leukine. Every FDA application for this active ingredient.
As of Nov 14, 2026, FDA lists 1 application for Sargramostim (sold as Leukine), first approved Mar 5, 1991, with 4 new uses approved and 0 published complete response letters.
| Leukine | Part D | $3.6M | +8% | 81 |
| Leukine | Part B | $917K | -35% | 132 |
| Naxitamab Enabled Transplant-Free Study in High-Risk NeuroblastomaNeuroblastoma · Giselle Sholler | Phase 2 | Recruiting | Nov 12, 2026 |
| Labyrinthin Vaccination in Veterans With Lung AdenocarcinomaType and Grade of Toxicities, Demographic and Background Characteristics, Advanced, Metastatic, Recurrent Adenocarcinoma and Malignant Solid Neoplasm · VA Office of Research and Development | Phase 2 | Not yet recruiting | Oct 6, 2026 |
| Hypofractionated Radiotherapy Plus GM-CSF, Pomalidomide and Glofitamab for Newly Diagnosed PCNS-DLBCLDLBCL - Diffuse Large B Cell Lymphoma, PCNSL (Primary CNS Lymphoma) · The First Affiliated Hospital of Xiamen University | Phase 2 | Recruiting | Aug 6, 2026 |
| A Vaccine (STEMVAC) for Improving Survival in Patients With Triple-Negative Breast Cancer and Moderate or Extensive Residual Cancer BurdenAnatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8 · University of Washington | Phase 2 | Not yet recruiting | Jul 23, 2026 |
| Patients Between the Ages of 12 Months to 21 Years With Newly-Diagnosed High-Risk Neuroblastoma Will Receive Children's Oncology Group (COG) Type Recommended Therapy With the Addition of Naxitamab and Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) to Induction Cycles 1-5High-Risk Neuroblastoma · Shaare Zedek Medical Center | Phase 2 | Recruiting | Apr 17, 2026 |
| Testing the Addition of Iberdomide to Therapy in People With Neuroblastoma That Has Come Back, Not Responded to Treatment, or Gotten WorseRecurrent Ganglioneuroblastoma, Recurrent Neuroblastoma · National Cancer Institute (NCI) | Phase 1 / Phase 2 | Recruiting | Feb 27, 2026 |
| DC/MM Fusion Vaccine With BCMA CAR-T in R/R MMMultiple Myeloma, Refractory Multiple Myeloma · David Avigan | Phase 1 | Recruiting | Jan 29, 2026 |
| Adoptive T Cell Therapy With DC/AML Fusion Vaccine Plus Decitabine and Venetoclax in AMLAcute Myeloid Leukemia, Acute Myeloid Leukemia, in Relapse · David Avigan | Phase 1 | Recruiting | Jan 28, 2026 |
| Approved | Application | Sponsor | Supplements | Marketing |
|---|---|---|---|---|
| Mar 5, 1991 | LeukineBLA 103362 · New molecular entity | Berlex Labs | 8 | Marketed |
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Drugs@FDA
